Piramal Enterprises Ltd. (PEL) AI Stock Analysis

• Market Cap: ₹254.92B
• Dividend Yield: 0.98%
• Average Volume (3M): 20.60K
• Price to Earnings (P/E): 43.6
• Beta (1Y): 1.58
• Revenue Growth: 34.01%
• EPS Growth: N/A
• Country: IN
• Employees: 13,706
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.26
• Shares Outstanding: 226,677,700
• 10 Day Avg. Volume: 39,314
• 30 Day Avg. Volume: 20,599
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,226.00
• Price Target Upside: 9.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: ₹1,226.00 ▲(9.02% Upside)

Piramal Enterprises Ltd. faces significant financial challenges, with high leverage and cash flow issues being the primary concerns. Technical analysis indicates bearish momentum, and the stock appears overvalued based on its P/E ratio. These factors contribute to a cautious outlook for the stock.

Piramal Enterprises Ltd. Business Overview & Revenue Model

Company Description

Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

How the Company Makes Money

Piramal Enterprises Ltd. generates revenue through its diversified operations in financial services and pharmaceuticals. In the financial services segment, the company earns from lending activities, structured credit solutions, and asset management services. This includes interest income from loans, fees from advisory services, and performance-based earnings from managing alternative investment funds. In the pharmaceutical sector, PEL derives income from the sales of its contract development and manufacturing services and its range of healthcare products. Strategic partnerships, including joint ventures and collaborations with other industry players, also contribute to its revenue streams, enabling market expansion and operational efficiencies.

Piramal Enterprises Ltd. Financial Statement Overview

Summary

Piramal Enterprises Ltd. demonstrates operational efficiency through strong gross and EBIT margins. However, inconsistent revenue growth, fluctuating profitability, high leverage, and cash flow issues highlight financial instability. Improving cash flow and reducing debt are crucial for stability.

Income Statement

The company has shown strong gross and EBIT margins, indicating operational efficiency. However, the net profit margin has fluctuated significantly, with a notable net loss in 2024. Revenue growth is inconsistent, with recent declines impacting the score.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage. However, the equity ratio remains moderate, reflecting a balance in funding through equity. Return on equity has been volatile, with periods of strong performance followed by losses.

Cash Flow

The cash flow statement reveals challenges, with negative free cash flow and significant negative operating cash flow in recent years. The company's ability to convert net income to cash is limited, impacting overall cash flow stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	89.16B	89.16B	78.79B	80.32B	76.43B	127.71B
Gross Profit	72.59B	72.59B	64.72B	58.11B	57.41B	89.03B
EBITDA	61.40B	61.40B	18.94B	86.85B	56.55B	81.05B
Net Income	4.85B	4.85B	-16.84B	99.69B	19.23B	13.32B
Balance Sheet
Total Assets	949.43B	949.43B	826.05B	837.52B	998.73B	771.19B
Cash, Cash Equivalents and Short-Term Investments	62.76B	62.76B	54.32B	46.49B	71.59B	105.87B
Total Debt	654.88B	654.88B	535.86B	495.11B	557.03B	395.57B
Total Liabilities	678.47B	678.47B	560.48B	526.93B	630.36B	419.80B
Stockholders Equity	270.96B	270.96B	265.57B	310.59B	354.89B	340.18B
Cash Flow
Free Cash Flow	0.00	-83.65B	-12.43B	11.57B	77.91B	30.69B
Operating Cash Flow	0.00	-80.91B	264.30M	13.59B	87.50B	36.65B
Investing Cash Flow	0.00	-18.54B	-18.72B	-3.51B	-21.31B	-27.72B
Financing Cash Flow	0.00	116.64B	13.90B	-33.25B	-67.74B	20.72B

Piramal Enterprises Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1124.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PEL, the sentiment is Neutral. The current price of 1124.6 is above the 20-day moving average (MA) of 1111.06, below the 50-day MA of 1182.62, and above the 200-day MA of 1077.57, indicating a neutral trend. The MACD of -6.77 indicates Negative momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 63.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:PEL.

Piramal Enterprises Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPCALAB	66 Neutral	354.70B	45.56	10.62%	0.29%	11.49%	35.00%
APLLTD	60 Neutral	186.73B	30.96	11.24%	1.17%	8.20%	-4.26%
PPLPHARMA	60 Neutral	269.64B	274.23	1.12%	0.07%	9.08%	249.08%
PEL	57 Neutral	₹254.92B	43.64		0.98%	34.01%	―
GLENMARK	54 Neutral	568.45B	75.42	11.83%	0.12%	10.99%	0.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Piramal Enterprises Ltd. Corporate Events

Piramal Enterprises Schedules Investor Meeting with Axis Capital

Piramal Enterprises Ltd. has announced a scheduled group investor meeting organized by Axis Capital on August 25, 2025, in Mumbai. This meeting is part of the company’s efforts to engage with analysts and institutional investors, potentially impacting its market positioning and stakeholder relations.

Piramal Enterprises Releases Conference Call Recording on Q1 Financial Results

Piramal Enterprises Limited has announced the availability of the audio recording of its conference call discussing the unaudited financial results for the quarter ending June 30, 2025. This move is part of the company’s compliance with regulatory requirements, ensuring transparency and accessibility for stakeholders interested in the company’s financial performance.